Nataliya Zelinska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nataliya Zelinska has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Evgenia Globa
Ukrainian Scientific and Practical Center of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine
13 shared publications Zvi Zadik
Pediatric Endocrinology, Kaplan Medical Center , Rehovot 76100
4 shared publicationsJulia Skorodok
St. Petersburg State Pediatric Medical Academy, St. Petersburg 194100, Russia
3 shared publicationsLeanne Amitzi
OPKO Biologics, Kiryat Gat 8211804, Israel
3 shared publicationsOleg Malievsky
Bashkir State Medical University, Ufa 450000, Russia
3 shared publicationsOren Hershkovitz
OPKO Biologics, Kiryat Gat 8211804, Israel
3 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open-Label 9-Year Follow-Up Extension Phase 2 Study of Once-Weekly Somatrogon in Children With Growth Hormone Deficiency
Context: : Growth hormone deficiency (GHD) can lead to significant growth and developmental issues, necessitating long-term treatment. Once-weekly somatrogon is a long-acting recombinant human growth hormone analogue, approved for treatment of children with GHD. Objective: : Assess the long-term safety and efficacy of somatrogon in children with GHD. Design: : Open-label extension (OLE) study following an initial 12-month open-label phase 2 study. Setting: : Conducted at 14 centers across Hungary, Bulgaria, Belarus, Ukraine, Russia, Greece, and the US. Patients or Other Participants: : Fifty-three children with GHD (67.9% male, mean age 6.0±2.1 years) completed the phase 2 study and 48 entered the OLE. Intervention(s): : Participants received once-weekly somatrogon for up to 9 years. Main Outcome Measure(s): : Safety endpoints included adverse events (AEs), antidrug antibodies (ADAs), local site injection reactions, and insulin-like growth factor-I SDS. Efficacy endpoints included annual height velocity (HV), change in height SDS, and annual bone maturation. Results: Treatment-emergent AEs (TEAEs) incidence was 52.1% at OLE year (Y) 1, decreasing to 23.8% by Y9. Serious AEs were rare with only isolated cases reported. ADA positivity was observed, but no neutralizing antibodies were found. No correlation between ADA presence and TEAE incidence or severity was noted, nor was there a difference in growth based on ADA presence. Mean annualized HV remained > 5 cm/year, and height SDS improved from -4.0 at baseline to -0.2 by Y8. No changes in the ratio of bone age/chronological age were observed. Conclusions: Once-weekly somatrogon is a well-tolerated and a viable long-term treatment for GHD in children. More real-world data are needed. Clinicaltrials.gov: NCT01592500.
- 29 June 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open AccessOpen-Label 9-Year Follow-Up Extension Phase 2 Study of Once-Weekly Somatrogon in Children With Growth Hormone Deficiency
Context: : Growth hormone deficiency (GHD) can lead to significant growth and developmental issues, necessitating long-term treatment. Once-weekly somatrogon is a long-acting recombinant human growth hormone analogue, approved for treatment of children with GHD. Objective: : Assess the long-term safety and efficacy of somatrogon in children with GHD. Design: : Open-label extension (OLE) study following an initial 12-month open-label phase 2 study. Setting: : Conducted at 14 centers across Hungary, Bulgaria, Belarus, Ukraine, Russia, Greece, and the US. Patients or Other Participants: : Fifty-three children with GHD (67.9% male, mean age 6.0±2.1 years) completed the phase 2 study and 48 entered the OLE. Intervention(s): : Participants received once-weekly somatrogon for up to 9 years. Main Outcome Measure(s): : Safety endpoints included adverse events (AEs), antidrug antibodies (ADAs), local site injection reactions, and insulin-like growth factor-I SDS. Efficacy endpoints included annual height velocity (HV), change in height SDS, and annual bone maturation. Results: Treatment-emergent AEs (TEAEs) incidence was 52.1% at OLE year (Y) 1, decreasing to 23.8% by Y9. Serious AEs were rare with only isolated cases reported. ADA positivity was observed, but no neutralizing antibodies were found. No correlation between ADA presence and TEAE incidence or severity was noted, nor was there a difference in growth based on ADA presence. Mean annualized HV remained > 5 cm/year, and height SDS improved from -4.0 at baseline to -0.2 by Y8. No changes in the ratio of bone age/chronological age were observed. Conclusions: Once-weekly somatrogon is a well-tolerated and a viable long-term treatment for GHD in children. More real-world data are needed. Clinicaltrials.gov: NCT01592500.
- Open Access
- 31 July 2025
- Published by Publishing Company VIT-A-POL in Ukrainian Journal of Pediatric Endocrinology
- No. 2,p. 4-11
Insulin therapy in children and adolescents with diabetes mellitus and analysis of treatment quality based on the patient registry data for 2021—2023
- 31 July 2025
- Published by Publishing Company VIT-A-POL in Ukrainian Journal of Pediatric Endocrinology
- No. 2,p. 4-11
Open AccessInsulin therapy in children and adolescents with diabetes mellitus and analysis of treatment quality based on the patient registry data for 2021—2023
- Open Access
- 27 December 2024
- Published by Publishing Company VIT-A-POL in Ukrainian Journal of Pediatric Endocrinology
- No. 4,p. 4-9
Pediatric endocrinology in Ukraine in 2021—2023: statistics and specialized care
- 27 December 2024
- Published by Publishing Company VIT-A-POL in Ukrainian Journal of Pediatric Endocrinology
- No. 4,p. 4-9
Open AccessPediatric endocrinology in Ukraine in 2021—2023: statistics and specialized care
- Open Access
- 28 December 2023
- Published by Odesa I.I. Mechnikov National University in Odesa National University Herald. Biology
- Vol. 28 (2(53)) , 155-170
BIOLOGY SECTION – “THE IMPORTANCE OF G. GAMOW'S IDEAS FOR BIOLOGY OF THE 21st CENTURY” XXIII INTERNATIONAL CONFERENCE NAMED BY G. GAMOW THAT TOOK PLACE IN AUGUST 2023 AT ODESA I. I. MECHNIKOV NATIONAL UNIVERSITY
Біологічна секція щорічної Гамовської конференції проходила 23 серпня 2023 року в режимі on-line на платформі Zoom. В роботі секції брали участь 44 учасники з України, Німеччини, Великобританії, Швейцарії, Польщі, США, Канади, Аргентини і Казахстану. Робота секції поділялася на модулі – з молекулярної генетики рослин, молекулярної генетики мікроорганізмів – продуцентів антибіотиків, молекулярно-генетичних досліджень людини, що проводяться для вирішення питань генної діагностики і терапії людини. Також на конференції обговорювали окремі питання історії розвитку молекулярних досліджень вірусів. Серед доповідачів свої дослідження представляли провідні науковці Інституту генетики рослин і досліджень сільськогосподарських рослин імені Лейбніца (IPK) в м. Гатерслебен (Німеччина). Керівник відділу Репродуктивної біології рослин IPK професор Й. Кумлегн виступив з доповіддю – «Сas ендонуклеазна технологія у зернових: від сайт-спрямованого мутагенезу до більш прецизійного редагування геному», в якій продемонстрував такі досягнення відділу, як створення шестирядного ячменю з дворядного, отримання певних сортів голозерного ячменю. Представлені результати вражають не тільки тому, що вони з’явилися майже одразу після оголошення Нобелівської премії у 2020 році за відкриття механізму CRISPR / Cas редагування геномів, але й прецизійною точністю виконаного редагування, коли заміна фактично одного нуклеотиду призвела до появи певних бажаних ознак у рослин. Про складнощі з визначенням гена короткостебловості пшениці Rht 8 розповів проф. C. Гріффітс (Центр Джона Іннеса, м. Норвіч, Велика Британія) в доповіді «Гойдалка Rht 8». Цікаві доповіді представили науковці з IPK: професор М. Нагель – «Зміни метаболітів в насінні після 40 років довготривалого зберігання в холоді пшениці та ячменю» і др. М. Шiренбек – «Генетична дисекція стійкості паростків до посухового стресу у панелі сортів озимої пшениці». Родзинкою виконаних др. М. Шiренбеком зі співавторами досліджень, на наш погляд, було те, що поряд з сортами пшениці з низки Європейських країн та країн Південної Америки вивчалися і українські сорти пшениці, деякі з котрих проявили себе як посухостійкі. В доповіді др. Г. Чеботар (ІPK) «Як знайти ген-кандидат – GWAS – з особливим наголосом на збереженні життєздатності ячменю», наочно було продемонстровано алгоритм й можливості GWAS для пошуку маркерних послідовностей генів кандидатів, що впливають на життєздатність насіння ячменю при довготривалому зберіганні. Аспірантка кафедри молекулярної біології, біохімії та генетики ОНУ імені І. І. Мечникова (м. Одеса) Ю. Попович представила результати щодо ефективності застосування самостійно розроблених праймерів для визначення алельного стану багатокопійних генів гліадинів в сортах пшениці, а професор С. Оконь з Природничого університету (м. Люблін, Польща) розповіла про визначення й локалізацію нових генів стійкості до борошнистої роси у вівса – «Ідентифікація та хромосомна локалізація генів стійкості до борошнистої роси Pm11 та Pm12 у вівса (Avena sativa L.)» Питання молекулярної організації і еволюції нуклеотидних послідовностей генів 5S РНК у межах триби Limonieae (Plumbaginaceae) розглянув в доповіді «5S рибосомна ДНК у трибі Limonieae (Plumbaginaceae): молекулярна організація, поліморфізм та таксономічне застосування» доцент, к.б.н. Ю.О. Тинкевич, який продемонстрував результати досліджень, виконаних в Чернівецькому національному університеті імені Юрія Федьковича на кафедрі молекулярної генетики та біотехнології. Надзвичайно велику зацікавленість викликала доповідь «Динаміка геному рослин та епігеному в контексті зміни клімату» професора Е. Бучера, керівника групи з дослідження динаміки геному злаків корпорації Agroscope, Швейцарія. У наступному інформаційному модулі на засіданні секції виступили молоді науковці Львівського національного університету імені Івана Франка – к.б.н. О. Ющук з доповіддю «Гени стійкості до глікопептидних антибіотиків: оновлена точка зору» і аспірантка Г. Качор – «Геномна характеристика штаму актиноміцетів Mumia sp. Pv 4-285, виділеного з ризосфери Phyllostachys viridiglaucescens». Молоді дослідники продемонстрували традиційно високий рівень молекулярно-біологічних досліджень актиноміцетів, що вивчаються на кафедрі генетики та біотехнології ЛНУ. Питання з молекулярної генетики людини розглядалися в двох доповідях. У доповіді, представленій Д. Сірохою «Oлігогенний вплив мутацій KIAA1210 та CFAP47 на розвиток особливостей DSD у пацієнта з мутацією C.34G>C GATA4» згідно досліджень, виконаних під керівництвом професора Л. Лівшиць, яка очолює лабораторію геноміки людини в Інституті молекулярної біології і генетики НАН України (м. Київ) і в доповіді др. Ю. Мончака – «Молекулярний ДНК-трекінг трансплантації стовбурових клітин пуповини з мультидонорських пулів: коли одного донора замало» стосовно результатів досліджень, що виконані у відділі експериментальної медицини в МакГілл університеті, (м. Монреаль, Канада). Обидві доповіді продемонстрували визначальну важливість дослідження нуклеотидних послідовностей певних молекулярних локусів. На завершення роботи біологічної секції пролунала доповідь професора Дж. Сегре з Пенсільванського університету, якій вже вдруге бере участь в Гамовській конференції і є автором біографічної книги «Звичайні генії: як два диваки проклали шляхи сучасної науки», присвяченої Георгію Гамову і Максу Дельбрюку. Цього року професор Дж. Сегре в доповіді «Друг Джорджа Гамова Макс Дельбрюк, засновник сучасних досліджень вірусів» приділив визначну увагу другу Георгія Гамова, лауреату Нобелевської премії Максу Дельбрюку.
- 28 December 2023
- Published by Odesa I.I. Mechnikov National University in Odesa National University Herald. Biology
- Vol. 28 (2(53)) , 155-170
Open AccessBIOLOGY SECTION – “THE IMPORTANCE OF G. GAMOW'S IDEAS FOR BIOLOGY OF THE 21st CENTURY” XXIII INTERNATIONAL CONFERENCE NAMED BY G. GAMOW THAT TOOK PLACE IN AUGUST 2023 AT ODESA I. I. MECHNIKOV NATIONAL UNIVERSITY
Біологічна секція щорічної Гамовської конференції проходила 23 серпня 2023 року в режимі on-line на платформі Zoom. В роботі секції брали участь 44 учасники з України, Німеччини, Великобританії, Швейцарії, Польщі, США, Канади, Аргентини і Казахстану. Робота секції поділялася на модулі – з молекулярної генетики рослин, молекулярної генетики мікроорганізмів – продуцентів антибіотиків, молекулярно-генетичних досліджень людини, що проводяться для вирішення питань генної діагностики і терапії людини. Також на конференції обговорювали окремі питання історії розвитку молекулярних досліджень вірусів. Серед доповідачів свої дослідження представляли провідні науковці Інституту генетики рослин і досліджень сільськогосподарських рослин імені Лейбніца (IPK) в м. Гатерслебен (Німеччина). Керівник відділу Репродуктивної біології рослин IPK професор Й. Кумлегн виступив з доповіддю – «Сas ендонуклеазна технологія у зернових: від сайт-спрямованого мутагенезу до більш прецизійного редагування геному», в якій продемонстрував такі досягнення відділу, як створення шестирядного ячменю з дворядного, отримання певних сортів голозерного ячменю. Представлені результати вражають не тільки тому, що вони з’явилися майже одразу після оголошення Нобелівської премії у 2020 році за відкриття механізму CRISPR / Cas редагування геномів, але й прецизійною точністю виконаного редагування, коли заміна фактично одного нуклеотиду призвела до появи певних бажаних ознак у рослин. Про складнощі з визначенням гена короткостебловості пшениці Rht 8 розповів проф. C. Гріффітс (Центр Джона Іннеса, м. Норвіч, Велика Британія) в доповіді «Гойдалка Rht 8». Цікаві доповіді представили науковці з IPK: професор М. Нагель – «Зміни метаболітів в насінні після 40 років довготривалого зберігання в холоді пшениці та ячменю» і др. М. Шiренбек – «Генетична дисекція стійкості паростків до посухового стресу у панелі сортів озимої пшениці». Родзинкою виконаних др. М. Шiренбеком зі співавторами досліджень, на наш погляд, було те, що поряд з сортами пшениці з низки Європейських країн та країн Південної Америки вивчалися і українські сорти пшениці, деякі з котрих проявили себе як посухостійкі. В доповіді др. Г. Чеботар (ІPK) «Як знайти ген-кандидат – GWAS – з особливим наголосом на збереженні життєздатності ячменю», наочно було продемонстровано алгоритм й можливості GWAS для пошуку маркерних послідовностей генів кандидатів, що впливають на життєздатність насіння ячменю при довготривалому зберіганні. Аспірантка кафедри молекулярної біології, біохімії та генетики ОНУ імені І. І. Мечникова (м. Одеса) Ю. Попович представила результати щодо ефективності застосування самостійно розроблених праймерів для визначення алельного стану багатокопійних генів гліадинів в сортах пшениці, а професор С. Оконь з Природничого університету (м. Люблін, Польща) розповіла про визначення й локалізацію нових генів стійкості до борошнистої роси у вівса – «Ідентифікація та хромосомна локалізація генів стійкості до борошнистої роси Pm11 та Pm12 у вівса (Avena sativa L.)» Питання молекулярної організації і еволюції нуклеотидних послідовностей генів 5S РНК у межах триби Limonieae (Plumbaginaceae) розглянув в доповіді «5S рибосомна ДНК у трибі Limonieae (Plumbaginaceae): молекулярна організація, поліморфізм та таксономічне застосування» доцент, к.б.н. Ю.О. Тинкевич, який продемонстрував результати досліджень, виконаних в Чернівецькому національному університеті імені Юрія Федьковича на кафедрі молекулярної генетики та біотехнології. Надзвичайно велику зацікавленість викликала доповідь «Динаміка геному рослин та епігеному в контексті зміни клімату» професора Е. Бучера, керівника групи з дослідження динаміки геному злаків корпорації Agroscope, Швейцарія. У наступному інформаційному модулі на засіданні секції виступили молоді науковці Львівського національного університету імені Івана Франка – к.б.н. О. Ющук з доповіддю «Гени стійкості до глікопептидних антибіотиків: оновлена точка зору» і аспірантка Г. Качор – «Геномна характеристика штаму актиноміцетів Mumia sp. Pv 4-285, виділеного з ризосфери Phyllostachys viridiglaucescens». Молоді дослідники продемонстрували традиційно високий рівень молекулярно-біологічних досліджень актиноміцетів, що вивчаються на кафедрі генетики та біотехнології ЛНУ. Питання з молекулярної генетики людини розглядалися в двох доповідях. У доповіді, представленій Д. Сірохою «Oлігогенний вплив мутацій KIAA1210 та CFAP47 на розвиток особливостей DSD у пацієнта з мутацією C.34G>C GATA4» згідно досліджень, виконаних під керівництвом професора Л. Лівшиць, яка очолює лабораторію геноміки людини в Інституті молекулярної біології і генетики НАН України (м. Київ) і в доповіді др. Ю. Мончака – «Молекулярний ДНК-трекінг трансплантації стовбурових клітин пуповини з мультидонорських пулів: коли одного донора замало» стосовно результатів досліджень, що виконані у відділі експериментальної медицини в МакГілл університеті, (м. Монреаль, Канада). Обидві доповіді продемонстрували визначальну важливість дослідження нуклеотидних послідовностей певних молекулярних локусів. На завершення роботи біологічної секції пролунала доповідь професора Дж. Сегре з Пенсільванського університету, якій вже вдруге бере участь в Гамовській конференції і є автором біографічної книги «Звичайні генії: як два диваки проклали шляхи сучасної науки», присвяченої Георгію Гамову і Максу Дельбрюку. Цього року професор Дж. Сегре в доповіді «Друг Джорджа Гамова Макс Дельбрюк, засновник сучасних досліджень вірусів» приділив визначну увагу другу Георгія Гамова, лауреату Нобелевської премії Максу Дельбрюку.
- Open Access
- 18 July 2023
- Published by Publishing Company VIT-A-POL in Ukrainian Journal of Pediatric Endocrinology
- No. 2,p. 4-10
Pediatric endocrinology in Ukraine for 2002—2022 years
- 18 July 2023
- Published by Publishing Company VIT-A-POL in Ukrainian Journal of Pediatric Endocrinology
- No. 2,p. 4-10
Open AccessPediatric endocrinology in Ukraine for 2002—2022 years
- Open Access
- 30 March 2023
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 69-78
Papillary thyroid cancer in children. Clinical cases
Thyroid cancer (TC) is the most common endocrine tumor in pediatric patients. Papillary carcinoma accounts for the highest rate among differentiated TCs (80—90%). Papillary thyroid cancer in children is clinically different from this pathology in adults. In comparison with adults, papillary thyroid cancer in children is diagnosed at later stages and is associated with a more aggressive course of the disease. Despite the high frequency of metastases and recurrences of papillary thyroid cancer in children, the prognosis remains favorable. In Ukraine, 10 years after the accident at the Chernobyl nuclear power plant, the average incidence rates of papillary thyroid cancer among children of all ages gradually decreased, but since 2010—2011, a negative trend towards an increase in the number of new cases of pathology, especially children under 14 years of age, has been restored. Several studies suggest that the increase in the incidence of papillary thyroid cancer is only partially explained by the increase in the number of preventive examinations performed, as there is also an increase in the detection of large tumors and the diagnosis of advanced stages of the disease.Over the past 14 years, 759 children aged 3 to 18 from all regions of Ukraine were operated in the clinic of the Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine (Center). From them, based on the results of histopathological examinations, papillary thyroid cancer was diagnosed in 290 (38.2%) children (including 73.45% girls and 26.55% boys). In most cases, the disease was diagnosed during adolescence, except for isolated cases among children of primary school and preschool age. The paper presents two clinical cases.Annual preventive thyroid ultrasound investigation is required for early diagnosis of nodular goiter, including malignant thyroid tumors, especially in children with a burdened family history of these tumors. Any nodular goiter in children should be considered potentially malignant until its benign nature is proven by appropriate qualified investigations. To ensure proper and timely verification of malignant thyroid tumors in pediatric patients, to avoid unjustified (insufficient or excessive) surgical treatment of children with thyroid tumors, such patients should be referred to medical institutions with modern diagnostic capabilities and expert‑level surgical experience in the treatment of children with nodular goiter and malignant thyroid tumors.
- 30 March 2023
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 69-78
Open AccessPapillary thyroid cancer in children. Clinical cases
Thyroid cancer (TC) is the most common endocrine tumor in pediatric patients. Papillary carcinoma accounts for the highest rate among differentiated TCs (80—90%). Papillary thyroid cancer in children is clinically different from this pathology in adults. In comparison with adults, papillary thyroid cancer in children is diagnosed at later stages and is associated with a more aggressive course of the disease. Despite the high frequency of metastases and recurrences of papillary thyroid cancer in children, the prognosis remains favorable. In Ukraine, 10 years after the accident at the Chernobyl nuclear power plant, the average incidence rates of papillary thyroid cancer among children of all ages gradually decreased, but since 2010—2011, a negative trend towards an increase in the number of new cases of pathology, especially children under 14 years of age, has been restored. Several studies suggest that the increase in the incidence of papillary thyroid cancer is only partially explained by the increase in the number of preventive examinations performed, as there is also an increase in the detection of large tumors and the diagnosis of advanced stages of the disease.Over the past 14 years, 759 children aged 3 to 18 from all regions of Ukraine were operated in the clinic of the Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine (Center). From them, based on the results of histopathological examinations, papillary thyroid cancer was diagnosed in 290 (38.2%) children (including 73.45% girls and 26.55% boys). In most cases, the disease was diagnosed during adolescence, except for isolated cases among children of primary school and preschool age. The paper presents two clinical cases.Annual preventive thyroid ultrasound investigation is required for early diagnosis of nodular goiter, including malignant thyroid tumors, especially in children with a burdened family history of these tumors. Any nodular goiter in children should be considered potentially malignant until its benign nature is proven by appropriate qualified investigations. To ensure proper and timely verification of malignant thyroid tumors in pediatric patients, to avoid unjustified (insufficient or excessive) surgical treatment of children with thyroid tumors, such patients should be referred to medical institutions with modern diagnostic capabilities and expert‑level surgical experience in the treatment of children with nodular goiter and malignant thyroid tumors.
- Open Access
- 30 September 2022
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 3,p. 47-67
Multifocal papillary thyroid cancer in children and adults. Lecture
Thyroid cancer is the 9th most common cancer in the world. Thus, in the year 2020, 586.000 cases of thyroid cancer were registered worldwide. The incidence rate among women is 10.1 per 100 thousand population, and among men — 3.1 per 100 thousand population. In Ukraine, in 2019, the standardized rate of incidence of thyroid cancer (world standard) was 6.9 per 100.000 population (2.8 among men, 10.5 among women). In the structure of the incidence of malignant neoplasms of the cervical spine, thyroid cancer ranks first place among women aged 18 — 29 (19.9 %), fourth among both men aged 18 — 29 (8.3 %, and women aged 30 — 54 (8.1 %). Over the past 40 years, increased incidence of thyroid cancer (in particular, papillary thyroid cancer) is observed in most countries, which can be explained by various factors, for example, overdiagnosis, a change in the prevalence of modified risk factors. In Ukraine, in the period from 1989 to 2012, the rate of incidence of papillary thyroid cancer among men increased by 115 %, among women — by 137 %, the annual increase in incidence of papillary thyroid cancer for men and women was 5 and 6 %, respectively. Multifocality in papillary thyroid cancer is a characteristic feature that is much more common in pediatric patients than in adults, but the number of studies in children is limited, which is associated with a lower prevalence of the disease in children. The results of investigations on the multifocality predictors and its role in influencing relapse, persistence, and survival in patients with papillary thyroid cancer are conflicting in both adults and pediatric population. Among the risk factors of multifocality, a smaller number of controversies concerns the links of metastasis in the lymphatic nodes, radiation in the anamnesis, childhood age, and for bilaterality — multifocality of the primary lobe and the presence of contralateral benign nodes (in adults). Other factors as predictors of multifocality have controversial significance and deserve attention in further research. The identification of reliable predictors of multifocality, especially with the help of preoperative data analysis, as well as multifocality risk stratification will facilitate the complex decision‑making process for the correct treatment tactics of children and adults with papillary thyroid cancer.
- 30 September 2022
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 3,p. 47-67
Open AccessMultifocal papillary thyroid cancer in children and adults. Lecture
Thyroid cancer is the 9th most common cancer in the world. Thus, in the year 2020, 586.000 cases of thyroid cancer were registered worldwide. The incidence rate among women is 10.1 per 100 thousand population, and among men — 3.1 per 100 thousand population. In Ukraine, in 2019, the standardized rate of incidence of thyroid cancer (world standard) was 6.9 per 100.000 population (2.8 among men, 10.5 among women). In the structure of the incidence of malignant neoplasms of the cervical spine, thyroid cancer ranks first place among women aged 18 — 29 (19.9 %), fourth among both men aged 18 — 29 (8.3 %, and women aged 30 — 54 (8.1 %). Over the past 40 years, increased incidence of thyroid cancer (in particular, papillary thyroid cancer) is observed in most countries, which can be explained by various factors, for example, overdiagnosis, a change in the prevalence of modified risk factors. In Ukraine, in the period from 1989 to 2012, the rate of incidence of papillary thyroid cancer among men increased by 115 %, among women — by 137 %, the annual increase in incidence of papillary thyroid cancer for men and women was 5 and 6 %, respectively. Multifocality in papillary thyroid cancer is a characteristic feature that is much more common in pediatric patients than in adults, but the number of studies in children is limited, which is associated with a lower prevalence of the disease in children. The results of investigations on the multifocality predictors and its role in influencing relapse, persistence, and survival in patients with papillary thyroid cancer are conflicting in both adults and pediatric population. Among the risk factors of multifocality, a smaller number of controversies concerns the links of metastasis in the lymphatic nodes, radiation in the anamnesis, childhood age, and for bilaterality — multifocality of the primary lobe and the presence of contralateral benign nodes (in adults). Other factors as predictors of multifocality have controversial significance and deserve attention in further research. The identification of reliable predictors of multifocality, especially with the help of preoperative data analysis, as well as multifocality risk stratification will facilitate the complex decision‑making process for the correct treatment tactics of children and adults with papillary thyroid cancer.
- 20 June 2022
- Published by Publishing Company VIT-A-POL in Ukrainian Journal of Pediatric Endocrinology
- No. 1-2,p. 6-16
Diseases of the endocrine system in children in Ukraine and specialized care to pediatric patients in 2021
The article provides information on the specialized medical care to children of various ages with endocrine pathology in Ukraine in the year 2021 and presents analysis of its dynamics over the past 8—10 years, based on the data of the official statistics of the Ministry of Health of Ukraine and Ukrainian databases of children with the rare (orphan) endocrine diseases. Information is provided on the provision of pediatric endocrinologists in various regions of Ukraine, the state of inpatient care by region, the indicators of neonatal screening for congenital hypothyroidism and congenital adrenal hyperplasia, and the incidence of endocrine pathology in children under 1 year of age.The article contains data on the dynamics of the prevalence of diabetes mellitus (DM) in children, its various types, malignant diseases of the endocrine glands, in particular thyroid cancer, a database of children with disorders of sexual differentiation (DSD), etc.It is noted that according to the register of children with DM in 2021, 11 193 patients under the age of 18 (15.0 per 10,000 child population) were registered, including 11 014 (14,74) children receiving insulin therapy (with DM type 1, other types of DM with the need for insulin treatment), 51 with DM type 2, 69 children with neonatal DM, of which the diagnosis was genetically confirmed in 40, and MODY was genetically confirmed in 59 children. The prevalence of DM among children aged 0—18 in 2021 increased by 46.2 % compared to 2012. The fastest growing prevalence and incidence of diabetes was among children under 6 years of age.Children with DSD undergo a detailed cytogenetic examination in the world’s leading genetic laboratories by specialists of the Department of Pediatric Endocrinology of the Ukrainian Scientific and Practical Center of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine. The database included 682 DSD patients, in particular with chromosomal DSD — 357 (52.3%, in particular 303 patients with Turner syndrome); 46, XY DSD — 119 patients (17.5%); 46,XX — 206 patients (30.2%) (of which 185 patients with DSD due to congenital adrenal hyperplasia).
- 20 June 2022
- Published by Publishing Company VIT-A-POL in Ukrainian Journal of Pediatric Endocrinology
- No. 1-2,p. 6-16
Diseases of the endocrine system in children in Ukraine and specialized care to pediatric patients in 2021
The article provides information on the specialized medical care to children of various ages with endocrine pathology in Ukraine in the year 2021 and presents analysis of its dynamics over the past 8—10 years, based on the data of the official statistics of the Ministry of Health of Ukraine and Ukrainian databases of children with the rare (orphan) endocrine diseases. Information is provided on the provision of pediatric endocrinologists in various regions of Ukraine, the state of inpatient care by region, the indicators of neonatal screening for congenital hypothyroidism and congenital adrenal hyperplasia, and the incidence of endocrine pathology in children under 1 year of age.The article contains data on the dynamics of the prevalence of diabetes mellitus (DM) in children, its various types, malignant diseases of the endocrine glands, in particular thyroid cancer, a database of children with disorders of sexual differentiation (DSD), etc.It is noted that according to the register of children with DM in 2021, 11 193 patients under the age of 18 (15.0 per 10,000 child population) were registered, including 11 014 (14,74) children receiving insulin therapy (with DM type 1, other types of DM with the need for insulin treatment), 51 with DM type 2, 69 children with neonatal DM, of which the diagnosis was genetically confirmed in 40, and MODY was genetically confirmed in 59 children. The prevalence of DM among children aged 0—18 in 2021 increased by 46.2 % compared to 2012. The fastest growing prevalence and incidence of diabetes was among children under 6 years of age.Children with DSD undergo a detailed cytogenetic examination in the world’s leading genetic laboratories by specialists of the Department of Pediatric Endocrinology of the Ukrainian Scientific and Practical Center of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine. The database included 682 DSD patients, in particular with chromosomal DSD — 357 (52.3%, in particular 303 patients with Turner syndrome); 46, XY DSD — 119 patients (17.5%); 46,XX — 206 patients (30.2%) (of which 185 patients with DSD due to congenital adrenal hyperplasia).
- Open Access
- 31 March 2022
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 89-102
Hypophosphatemic rickets. Clinical cases
Hypophosphatemic rickets (HR) is a genetically heterogeneous disease that is accompanied by hypophosphatemia, skeletal (rickets-like) disorders, growth retardation in children and adults and by damage of other organs and systems. Its incidence is 3.9 cases per 100.000 live births, and the prevalence ranges from 1.7 per 100,000 children to 4.8 per 100,000 people (children and adults). The study was aimed on the investigation of diagnostic features and treatment strategy of different HR subtypes and evaluation of the effectiveness of therapy. Three cases of patients with HR from two families have been described. Laboratory and instrumental investigations were used to confirm the HR. Genetic diagnosis was done using next-generation target sequencing (tNGS) (skeletal dysplasia panel). General clinical features of skeletal disorders (e.g. severe deformity of the lower extremities from early childhood) and growth retardation were observed in patients with HR. All patients had hypophosphatemia with normal/slightly elevated or decreased PTH levels. All patients underwent repeated surgical treatment (without appropriate laboratory and genetic testing and correction of phosphorus-calcium metabolism), which turned out to be ineffective and led to disability. In two patients from one family, genetic testing confirmed the presence of heterozygous pathogenic PHEX variant, and in one — a homozygous SLC34A3 variant. Normophosphatemia was achieved in a girl with SLC34A3 after starting therapy with the phosphorus supplements. In patients with PHEX variant, treatment with calcitriol, cholecalciferol and phosphorus supplements had little effect (P levels increased but normalization was not achieved), thus only burosumab proved to be rational therapy for such patients. Prior to any corrective surgery, a thorough laboratory and genetic examination should be performed to compensate the phosphorus-calcium metabolism. Timely initiation of pathogenetic conservative treatment can improve bone structure and final growth, as well as reduce the need for corrective surgery.
- 31 March 2022
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 89-102
Open AccessHypophosphatemic rickets. Clinical cases
Hypophosphatemic rickets (HR) is a genetically heterogeneous disease that is accompanied by hypophosphatemia, skeletal (rickets-like) disorders, growth retardation in children and adults and by damage of other organs and systems. Its incidence is 3.9 cases per 100.000 live births, and the prevalence ranges from 1.7 per 100,000 children to 4.8 per 100,000 people (children and adults). The study was aimed on the investigation of diagnostic features and treatment strategy of different HR subtypes and evaluation of the effectiveness of therapy. Three cases of patients with HR from two families have been described. Laboratory and instrumental investigations were used to confirm the HR. Genetic diagnosis was done using next-generation target sequencing (tNGS) (skeletal dysplasia panel). General clinical features of skeletal disorders (e.g. severe deformity of the lower extremities from early childhood) and growth retardation were observed in patients with HR. All patients had hypophosphatemia with normal/slightly elevated or decreased PTH levels. All patients underwent repeated surgical treatment (without appropriate laboratory and genetic testing and correction of phosphorus-calcium metabolism), which turned out to be ineffective and led to disability. In two patients from one family, genetic testing confirmed the presence of heterozygous pathogenic PHEX variant, and in one — a homozygous SLC34A3 variant. Normophosphatemia was achieved in a girl with SLC34A3 after starting therapy with the phosphorus supplements. In patients with PHEX variant, treatment with calcitriol, cholecalciferol and phosphorus supplements had little effect (P levels increased but normalization was not achieved), thus only burosumab proved to be rational therapy for such patients. Prior to any corrective surgery, a thorough laboratory and genetic examination should be performed to compensate the phosphorus-calcium metabolism. Timely initiation of pathogenetic conservative treatment can improve bone structure and final growth, as well as reduce the need for corrective surgery.
- Open Access
- 16 December 2021
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 4,p. 53-65
Congenital hypothalamic hypogonadism — a Kallmann syndrome in boys. Clinical cases
Central hypogonadism (CH) is a rare disease that occurs with a frequency of 1 : 8000 in women and 1 : 4000 in men. In 60 % of cases of CH, it is caused by Kallmann syndrome (KS) — a disease in which hypogonadotropic hypogonadism is combined with olfactory disorders (hyposmia or anosmia).Aim — to study clinical features, principles of diagnosis of CH/KS and evaluation of the effectiveness of various treatment. Materials and methods. 4 cases with CH/KS from three families had been described. Laboratory and instrumental investigations were used to confirm the KS; genetic diagnosis was performed using targeted next-generation sequencing (tNGS hypogonadotropic panel).Results. Patients with CH/KS had a wide spectrum of genital disorders (micropenia, cryptorchidism, microorchidism), which appeared at different age. Extragenital pathology was found in three of four patients: namely disorders of kidney, eye, respiratory system, hypoparathyroidism, hypothyroidism and epilepsy. It should be noted that all patients had olfactory disorders, which appeared in two of them only during a detailed survey after receiving genetic testing. In all patients, the diagnosis of CH was confirmed by the test with triptorelin 0.1. Also, all patients who underwent densitometry were found to have significant osteoporosis. In three patients, genetic testing confirmed hemizygous pathogenic variants in ANOS1 gene, while in one patient a heterozygous variant in FGFR1 gene was confirmed. After treatment with chorionic gonadotropin (HCG), two patients responded positively, with a descent of the testicles into the scrotum and an increase of testosterone level and testicular volume. However, in the other two patients there was no positive trend in treatment with HCG, therefore, the use of recombinant human FSH (r-FSH) in the form of priming and then further — in combination with HCG may be considered. Although the presence of severe microorchidism, cryptorchidism, low levels of AMH, inhibin B, and an unsatisfactory response to the previous treatment with HCG indicates extremely unfavorable prognosis. Therefore, in order to achieve the fertility in some patients with CH/KS, the most likely attempt is the use of assisted reproductive technologies.Conclusions. The leading problem in the treatment of patients with KS is their different response to hormone therapy, including different manifestations of the disease.
- 16 December 2021
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 4,p. 53-65
Open AccessCongenital hypothalamic hypogonadism — a Kallmann syndrome in boys. Clinical cases
Central hypogonadism (CH) is a rare disease that occurs with a frequency of 1 : 8000 in women and 1 : 4000 in men. In 60 % of cases of CH, it is caused by Kallmann syndrome (KS) — a disease in which hypogonadotropic hypogonadism is combined with olfactory disorders (hyposmia or anosmia).Aim — to study clinical features, principles of diagnosis of CH/KS and evaluation of the effectiveness of various treatment. Materials and methods. 4 cases with CH/KS from three families had been described. Laboratory and instrumental investigations were used to confirm the KS; genetic diagnosis was performed using targeted next-generation sequencing (tNGS hypogonadotropic panel).Results. Patients with CH/KS had a wide spectrum of genital disorders (micropenia, cryptorchidism, microorchidism), which appeared at different age. Extragenital pathology was found in three of four patients: namely disorders of kidney, eye, respiratory system, hypoparathyroidism, hypothyroidism and epilepsy. It should be noted that all patients had olfactory disorders, which appeared in two of them only during a detailed survey after receiving genetic testing. In all patients, the diagnosis of CH was confirmed by the test with triptorelin 0.1. Also, all patients who underwent densitometry were found to have significant osteoporosis. In three patients, genetic testing confirmed hemizygous pathogenic variants in ANOS1 gene, while in one patient a heterozygous variant in FGFR1 gene was confirmed. After treatment with chorionic gonadotropin (HCG), two patients responded positively, with a descent of the testicles into the scrotum and an increase of testosterone level and testicular volume. However, in the other two patients there was no positive trend in treatment with HCG, therefore, the use of recombinant human FSH (r-FSH) in the form of priming and then further — in combination with HCG may be considered. Although the presence of severe microorchidism, cryptorchidism, low levels of AMH, inhibin B, and an unsatisfactory response to the previous treatment with HCG indicates extremely unfavorable prognosis. Therefore, in order to achieve the fertility in some patients with CH/KS, the most likely attempt is the use of assisted reproductive technologies.Conclusions. The leading problem in the treatment of patients with KS is their different response to hormone therapy, including different manifestations of the disease.